Mohammed AlDawish
Overview
Explore the profile of Mohammed AlDawish including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
23
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Siraj S, Masoodi T, Siraj A, Azam S, Qadri Z, Parvathareddy S, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326735
Standard surgery followed by radioactive iodine (131I, RAI) therapy are not curative for 5−20% of papillary thyroid carcinoma (PTC) patients with RAI refractory disease. Early predictors indicating therapeutic response to...
2.
Alzahrani A, Alswailem M, Alghamdi B, Rafiullah R, AlDawish M, Al-Hindi H
Endocrine
. 2021 Oct;
75(2):478-486.
PMID: 34637071
Context: RET p.V804M is classified as a moderate risk mutation for familial medullary thyroid cancer (FMTC). There is a significant controversy on the management of patients carrying this mutation. We...
3.
Masoodi T, Siraj A, Siraj S, Azam S, Qadri Z, Parvathareddy S, et al.
Am J Hum Genet
. 2019 Nov;
105(5):959-973.
PMID: 31668701
Unlike many cancers, the pattern of tumor evolution in papillary thyroid cancer (PTC) and its potential role in relapse have not been elucidated. In this study, multi-region whole-exome sequencing (WES)...
4.
AlDawish M, Jha N, McEwan A, Severin D, Ghosh S, Morrish D
Endocr Res
. 2014 Jan;
39(4):157-63.
PMID: 24460082
Introduction: The study was aimed to determine the response and predictive risk factors of differentiated thyroid cancer (DTC) with measurable (0.4-2.0 µg/L) stimulated serum thyroglobulin (sTg) during the 10-24 months...